Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 350

Sort by

Sort Order Select

Journal Articles

CLEC2A, a validated cancer-specific antigen, is an ideal candidate for immunotherapeutic targeting in KMT2A-rearranged AML

Danielle Kirkey, Corinne Summers, Katherine Tarlock, Benjamin Huang, Grace Hawkins, Nika Panahi, Melia Blankenfeld, Isabel Lira, Bruce Liu, Seungmin Shin, Rhonda Ries, Jack H. Peplinski, Simona Manni, Pamela De Falco, Biagio De Angelis, Concetta Quintarelli, Franco Locatelli, Wei Li, Soheil Meshinchi

Blood (2025) 146 (Supplement 1): 4123.

https://doi.org/10.1182/blood-2025-4123

Published: 2025

Journal Articles

CD19 antigen: From tumor target to safety switch able to improve the safety profile of CAR T cell therapy

Simona Manni, Laura Iaffaldano, Maria Cecilia Quadraccia, Mariasole Aurigemma, Marika Guercio, Simona Caruso, Maria Antonietta De Ioris, Giada Del Baldo, Danielle Kirkey, Soheil Meshinchi, Pietro Merli, Marco Becilli, Francesca Del Bufalo, Biagio De Angelis, Franco Locatelli, Concetta Quintarelli

Blood (2025) 146 (Supplement 1): 2541.

https://doi.org/10.1182/blood-2025-2541

Published: 2025

Journal Articles

Optimal dosing of vobramitamab duocarmazine, a CD276 (B7-H3) antibody-drug conjugate, leads to durable eradication of Acute Myeloid Leukemia in preclinical xenograft models

Danielle Kirkey, Melia Blankenfeld, Deryk Loo, Isabel Lira, Grace Hawkins, Nika Panahi, Bruce Liu, Rhonda Ries, Jack H. Peplinski, Ezio Bonvini, Stephen Eck, Soheil Meshinchi

Blood (2025) 146 (Supplement 1): 5064.

https://doi.org/10.1182/blood-2025-5064

Published: 2025

Journal Articles

Clinical and molecular characterization of pure erythroid leukemias and sarcomas driven by nfia::CBFA2T3

Blood (2025) 146 (Supplement 1): 3510.

https://doi.org/10.1182/blood-2025-3510

Published: 2025

Journal Articles

Novel AML specific splice junction evaluation identifies ubc and DMBT1 as top proteins of clinical and therapeutic relevance in pediatric Acute Myeloid Leukemia

Ryanne Mulligan, Alyssa Obermayer, Xiaotu Ma, Paulo Rodriguez, Stanley Pounds, Rhonda Ries, Soheil Meshinchi, Timothy Shaw, Jatinder Lamba

Blood (2025) 146 (Supplement 1): 3497.

https://doi.org/10.1182/blood-2025-3497

Published: 2025

Journal Articles

Analysis of 3346 patients from the combined Children's Oncology Group AML studies further characterizes RAM immunophenotype AML and reveals other associated phenotypes and genetic drivers.

Andrew Menssen, Jacqueline Cook, Todd Alonzo, Robert Gerbing, Maria Pardo, Fan-Chi Hsu, Loren Lott, Fangyan Dai, Amenech Ashango, Thanh Thanh Dinh, Todd Cooper, Jessica Pollard, Katherine Tarlock, Lisa Brodersen, Michael Loken, Soheil Meshinchi, Chad Hudson

Blood (2025) 146 (Supplement 1): 337.

https://doi.org/10.1182/blood-2025-337

Published: 2025

Journal Articles

Paused RNA polymerase II enables flexible lineage decisions but also underlies oncogenic vulnerabilities in human hematopoiesis

Derek Janssens, Alexandria Eiken, Emma Baird, Harry Ashbaugh, Joanna Yi, Lev Silberstein, Soheil Meshinchi

Blood (2025) 146 (Supplement 1): 207.

https://doi.org/10.1182/blood-2025-207

Published: 2025

Journal Articles

HMGA1 chromatin regulators drive transcriptional networks governing cell cycle progression, immune escape, and menin-inhibitor resistance in KMT2A-r Acute Myeloid Leukemia

Bailey West, Li Luo, Zanshe Thompson, Yuze Du, Leslie Cope, Joseph Kim, Audrey-Ann Supreme, Faiza Shaik, Isha Maloo, Kathryn Mi, Alison Park, Soheil Meshinchi, Rhonda Ries, Jung-Hyun Kim, Linda Resar

Blood (2025) 146 (Supplement 1): 5027.

https://doi.org/10.1182/blood-2025-5027

Published: 2025

Journal Articles

Etoposide can be safely removed from induction chemotherapy without impacting survival for pediatric acute myeloid leukemia – a report from the Children's oncology group study AAML1831

Jenna Rossoff, Jing Chen, Todd Alonzo, Jim Wang, Richard Aplenc, Alan Gamis, Betsy Hirsch, Gordana Raca, Soheil Meshinchi, Anders Kolb, Sarah Tasian, Jessica Pollard, Matthew Kutny, Todd Cooper

Blood (2025) 146 (Supplement 1): 877.

https://doi.org/10.1182/blood-2025-877

Published: 2025

Journal Articles

Central nervous system disease status significantly impacts survival in pediatric acute myeloid leukemia: A report from Children's Oncology Group study AAML1831

Zachary Graff, Todd Alonzo, Robert Gerbing, Jim Wang, Jessica Pollard, Soheil Meshinchi, Alan Gamis, Richard Aplenc, Betsy Hirsch, Gordana Raca, Todd Cooper, Matthew Kutny

Blood (2025) 146 (Supplement 1): 872.

https://doi.org/10.1182/blood-2025-872

Published: 2025

Journal Articles

Impact of MDS-associated mutations and age on outcomes in NPM1-mutated AML

Vivian Liu, Megan Othus, Rhonda Ries, Jasmine Naru, Era Pogosova-Agadjanyan, Frederick Appelbaum, Lan Beppu, Thomas Chauncey, Harry Erba, John Godwin, Matthew Fitzgibbon, Min Fang, Stanley Lee, Anna Moseley, Jerald Radich, Cheryl Willman, Feinan Wu, Soheil Meshinchi, Derek Stirewalt

Blood (2025) 146 (Supplement 1): 6999.

https://doi.org/10.1182/blood-2025-6999

Published: 2025

Journal Articles

Prognostic relevance of epigenetic regulation of drug pharmacology and myeloid genes in pediatric AML

Naifah Alshameri, Francisco Marchi, Soheil Meshinchi, Xueyuan Cao, Jeffrey Rubnitz, Raul Ribeiro, Stanley Pounds, Jatinder Lamba

Blood (2025) 146 (Supplement 1): 1712.

https://doi.org/10.1182/blood-2025-1712

Published: 2025

Journal Articles

Fratricide-resistant anti-CD7 CAR-T cells for relapsed/refractory Acute Myeloid Leukemia

Marco Becilli, Chiara Rosignoli, Francesca Del Bufalo, Pietro Merli, Mattia Algeri, Daria Pagliara, Francesco Quagliarella, Federica Galaverna, Valentina Bertaina, Maria Giuseppina Cefalo, Clelia Geraci, Giovanna Del Principe, Biagio De Angelis, Chiara Agrati, Concetta Quintarelli, Soheil Meshinchi, Dario Campana, Franco Locatelli

Blood (2025) 146 (Supplement 1): 6946.

https://doi.org/10.1182/blood-2025-6946

Published: 2025

Journal Articles

Prevalence, clinical implications and impact of stem cell transplantation in UBTF-TD positive AML

Valeria Ceolin, Rhonda Ries, Jack H. Peplinski, Danielle Kirkey, Manuela Spadea, Vincenzo Apolito, Katherine Tarlock, Grace Hawkins, Melia Blankenfeld, Isabel Lira, Nika Panahi, Bruce Liu, Christian Thiede, Franco Locatelli, Francesco Saglio, Franca Fagioli, Soheil Meshinchi

Blood (2025) 146 (Supplement 1): 221.

https://doi.org/10.1182/blood-2025-221

Published: 2025

Journal Articles

FLT3 (CD135) expression in pediatric AML is associated with specific disease characteristics and worse outcome in the setting of sorafenib theraphy: A report from the Children's Oncology Group AAML1031 protocol.

Andrew Menssen, Amenech Ashango, Todd Alonzo, Robert Gerbing, Maria Pardo, Fan-Chi Hsu, Loren Lott, Fangyan Dai, Todd Cooper, Jessica Pollard, Katherine Tarlock, Richard Aplenc, Soheil Meshinchi, Lisa Brodersen, Michael Loken, Chad Hudson

Blood (2025) 146 (Supplement 1): 5256.

https://doi.org/10.1182/blood-2025-5256

Published: 2025

Journal Articles

Optimized treatment for pediatric patients with low-risk Acute Myeloid Leukemia: A report from the Children's oncology group study AAML1831

Reena Pabari, Chana Glasser, Todd Alonzo, Jim Wang, Richard Aplenc, Alan Gamis, Betsy Hirsch, Gordana Raca, Soheil Meshinchi, Kasey Leger, Kelly Getz, Anders Kolb, Jessica Pollard, Sarah Tasian, Matthew Kutny, Todd Cooper

Blood (2025) 146 (Supplement 1): 878.

https://doi.org/10.1182/blood-2025-878

Published: 2025

Journal Articles

A novel B7-H3-specific binder enables effective CAR T-cell therapy in an Acute Myeloid Leukemia experimental model

Pamela De Falco, Alessio Ottaviani, Michele Veneruso, Marilena Margiotta, Simona Manni, Marika Guercio, Francesca Del Bufalo, Roberta Castriconi, Cristina Bottino, Danielle Kirkey, Soheil Meshinchi, Pietro Merli, Marco Becilli, Biagio De Angelis, Concetta Quintarelli, Franco Locatelli

Blood (2025) 146 (Supplement 1): 6095.

https://doi.org/10.1182/blood-2025-6095

Published: 2025

Journal Articles

Post-transplant maintenance with sorafenib is safe and effective in pediatric patients with har FLT3/ITD AML: A report from the Children's oncology group protocol AAML1031

Caitlin Elgarten, Todd Alonzo, Robert Gerbing, John Choi, Brian Fisher, Betsy Hirsch, Samir Kahwash, John Levine, Lisa Brodersen, Michael Loken, Susana Raimondi, Katherine Tarlock, Andrew Wood, Lillian Sung, Todd Cooper, Alan Gamis, Soheil Meshinchi, Richard Aplenc, Jessica Pollard

Blood (2025) 146 (Supplement 1): 1644.

https://doi.org/10.1182/blood-2025-1644

Published: 2025

Journal Articles

NUP98::NSD1 fusion is associated with poor outcomes in Acute Myeloid Leukemia regardless of co-occurring mutations and treatment regimen

Katherine Tarlock, Danielle Kirkey, Rhonda Ries, Jack H. Peplinski, Todd Alonzo, Robert Gerbing, Jim Wang, Todd Cooper, Alan Gamis, Richard Aplenc, Martina Pigazzi, Franco Locatelli, Jessica Pollard, Soheil Meshinchi

Blood (2025) 146 (Supplement 1): 1702.

https://doi.org/10.1182/blood-2025-1702

Published: 2025

Journal Articles

TP53 inactivation confers resistance to the menin inhibitor revumenib in Acute Myeloid Leukemia

Jeevitha D'Souza, Camille Leung, Aishwarya Ballapuram, Abigail S. Lin, Alexa Rane Batingana, Adam Lamble, Rhonda Ries, Carolina Morales, Charisa Cottonham, Pranav Gona, Li Fan, Xiaotu Ma, Kevin Shannon, Soheil Meshinchi, Benjamin Braun, Benjamin Huang

Blood (2025) 146 (Supplement 1): 3470.

https://doi.org/10.1182/blood-2025-3470

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CLEC2A, a validated cancer-specific antigen, is an ideal candidate for immunotherapeutic targeting in KMT2A-rearranged AML

CD19 antigen: From tumor target to safety switch able to improve the safety profile of CAR T cell therapy

Optimal dosing of vobramitamab duocarmazine, a CD276 (B7-H3) antibody-drug conjugate, leads to durable eradication of Acute Myeloid Leukemia in preclinical xenograft models

Clinical and molecular characterization of pure erythroid leukemias and sarcomas driven by nfia::CBFA2T3

Novel AML specific splice junction evaluation identifies ubc and DMBT1 as top proteins of clinical and therapeutic relevance in pediatric Acute Myeloid Leukemia

Analysis of 3346 patients from the combined Children's Oncology Group AML studies further characterizes RAM immunophenotype AML and reveals other associated phenotypes and genetic drivers.

Paused RNA polymerase II enables flexible lineage decisions but also underlies oncogenic vulnerabilities in human hematopoiesis

HMGA1 chromatin regulators drive transcriptional networks governing cell cycle progression, immune escape, and menin-inhibitor resistance in KMT2A-r Acute Myeloid Leukemia

Etoposide can be safely removed from induction chemotherapy without impacting survival for pediatric acute myeloid leukemia – a report from the Children's oncology group study AAML1831

Central nervous system disease status significantly impacts survival in pediatric acute myeloid leukemia: A report from Children's Oncology Group study AAML1831

Impact of MDS-associated mutations and age on outcomes in NPM1-mutated AML

Prognostic relevance of epigenetic regulation of drug pharmacology and myeloid genes in pediatric AML

Fratricide-resistant anti-CD7 CAR-T cells for relapsed/refractory Acute Myeloid Leukemia

Prevalence, clinical implications and impact of stem cell transplantation in UBTF-TD positive AML

FLT3 (CD135) expression in pediatric AML is associated with specific disease characteristics and worse outcome in the setting of sorafenib theraphy: A report from the Children's Oncology Group AAML1031 protocol.

Optimized treatment for pediatric patients with low-risk Acute Myeloid Leukemia: A report from the Children's oncology group study AAML1831

A novel B7-H3-specific binder enables effective CAR T-cell therapy in an Acute Myeloid Leukemia experimental model

Post-transplant maintenance with sorafenib is safe and effective in pediatric patients with har FLT3/ITD AML: A report from the Children's oncology group protocol AAML1031

NUP98::NSD1 fusion is associated with poor outcomes in Acute Myeloid Leukemia regardless of co-occurring mutations and treatment regimen

TP53 inactivation confers resistance to the menin inhibitor revumenib in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only